OraSure Technologies (NASDAQ:OSUR) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen lowered shares of OraSure Technologies (NASDAQ:OSUR) from a hold rating to a sell rating in a research report sent to investors on Sunday morning.

Separately, Weiss Ratings upgraded OraSure Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, June 4th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Reduce” and an average price target of $3.00.

OraSure Technologies Stock Performance

OSUR opened at $4.05 on Friday. OraSure Technologies has a twelve month low of $2.08 and a twelve month high of $4.58. The firm has a market cap of $278.84 million, a price-to-earnings ratio of -3.89 and a beta of 1.01. The company has a fifty day simple moving average of $4.15 and a 200 day simple moving average of $3.38.

Insider Transactions at OraSure Technologies

In related news, Director Steven Kyle Boyd purchased 25,000 shares of the business’s stock in a transaction that occurred on Thursday, May 14th. The shares were purchased at an average cost of $2.99 per share, with a total value of $74,750.00. Following the completion of the acquisition, the director directly owned 113,462 shares of the company’s stock, valued at approximately $339,251.38. The trade was a 28.26% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 4.70% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On OraSure Technologies

Hedge funds and other institutional investors have recently modified their holdings of the stock. Sei Investments Co. lifted its position in shares of OraSure Technologies by 16.4% during the third quarter. Sei Investments Co. now owns 32,244 shares of the medical instruments supplier’s stock worth $103,000 after purchasing an additional 4,536 shares during the last quarter. Russell Investments Group Ltd. grew its stake in OraSure Technologies by 13.3% in the fourth quarter. Russell Investments Group Ltd. now owns 43,636 shares of the medical instruments supplier’s stock worth $106,000 after purchasing an additional 5,138 shares in the last quarter. Hsbc Holdings PLC increased its holdings in OraSure Technologies by 4.6% in the first quarter. Hsbc Holdings PLC now owns 141,309 shares of the medical instruments supplier’s stock valued at $421,000 after buying an additional 6,218 shares during the last quarter. BNP Paribas Financial Markets increased its holdings in OraSure Technologies by 102.2% in the third quarter. BNP Paribas Financial Markets now owns 15,275 shares of the medical instruments supplier’s stock valued at $49,000 after buying an additional 7,720 shares during the last quarter. Finally, Envestnet Asset Management Inc. increased its holdings in OraSure Technologies by 32.7% in the second quarter. Envestnet Asset Management Inc. now owns 33,018 shares of the medical instruments supplier’s stock valued at $99,000 after buying an additional 8,133 shares during the last quarter. Institutional investors own 93.50% of the company’s stock.

About OraSure Technologies

OraSure Technologies, Inc is a Bethlehem, Pennsylvania–based diagnostic and medical device company specializing in the development, manufacture and commercialization of point-of-care and self-testing products. Founded in 1988, OraSure has built a portfolio of oral fluid and other non-invasive specimen collection technologies that support the detection of infectious diseases, drugs of abuse, and health and wellness biomarkers.

The company’s flagship product, the OraQuick® rapid HIV test, was the first Food and Drug Administration–approved over-the-counter oral fluid test for the detection of HIV-1/2 antibodies.